Trial · NCT02006160
Effects of Dalfampridine on Cognition in Multiple Sclerosis
NCT02006160, Phase 2, Phase 3, Completed, State University of New York at Buffalo; results first posted 2019-05-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Dalfampridine on Cognition in Multiple Sclerosis. Trials, record NCT02006160. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02006160
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Dalfampridine on Cognition in Multiple Sclerosis
- NCT number
- NCT02006160
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 61 participants, actual
- Lead sponsor
- State University of New York at Buffalo
- Conditions
- Multiple Sclerosis
- Interventions
- dalfampridine, placebo
- First posted
- 2013-12-10
- Last updated
- 2020-10-01
- Results first posted
- 2019-05-07
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Symbol Digit Modalities Test | Week 0, Week 12 | The Symbol Digit Modalities Test is a measure of cognitive processing speed. The outcome is the total number of correct digit substitutions in 90 seconds, with a possible total range of 0-120. Higher values reflect a better score/outcome than lower scores. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Symbol Digit Modalities Test | Week 0, Week 12 | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Symbol Digit Modalities Test | Treatment | Week 0 | 41.18 | Standard Deviation 10.67 | score on a scale |
| Symbol Digit Modalities Test | Control | Week 0 | 35.06 | Standard Deviation 12.51 | score on a scale |
| Symbol Digit Modalities Test | Treatment | Week 12 | 45.05 | Standard Deviation 11.09 | score on a scale |
| Symbol Digit Modalities Test | Control | Week 12 | 38.63 | Standard Deviation 10.82 | score on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment | 45 | |
| Overall Study | STARTED | Control | 16 | |
| Overall Study | COMPLETED | Treatment | 41 | |
| Overall Study | COMPLETED | Control | 16 | |
| Overall Study | NOT COMPLETED | Treatment | 4 | |
| Overall Study | NOT COMPLETED | Control | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | General disorders | Treatment | 1 | 45 | 1 |
| other | Headache | General disorders | Control | 0 | 16 | 0 |
| other | Dizziness | General disorders | Treatment | 2 | 45 | 2 |
| other | Dizziness | General disorders | Control | 16 | ||
| other | Tremors | General disorders | Treatment | 1 | 45 | 1 |
| other | Tremors | General disorders | Control | 16 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment | ||
| Total, all-cause mortality | Control | ||
| Total, other adverse events | Treatment | 2 | 45 |
| Total, other adverse events | Control | 0 | 16 |
| Total, serious adverse events | Treatment | 0 | 45 |
| Total, serious adverse events | Control | 0 | 16 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30566030 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Treatment vs Control: serious adverse events |
Source Trial comparisons
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Symbol Coding | Primary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02006160
GET https://conductscience.org/api/trials/v1/NCT02006160/registered